284 related articles for article (PubMed ID: 38571964)
1. Immune regulation and therapeutic application of T regulatory cells in liver diseases.
Ajith A; Merimi M; Arki MK; Hossein-Khannazer N; Najar M; Vosough M; Sokal EM; Najimi M
Front Immunol; 2024; 15():1371089. PubMed ID: 38571964
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
[TBL] [Abstract][Full Text] [Related]
3. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
[TBL] [Abstract][Full Text] [Related]
5. Increased frequency of Foxp3+ regulatory T cells in mice with hepatocellular carcinoma.
Du Y; Chen X; Huang ZM; Ye XH; Niu Q
Asian Pac J Cancer Prev; 2012; 13(8):3815-9. PubMed ID: 23098476
[TBL] [Abstract][Full Text] [Related]
6. Increased frequency of CD4+CD25(high)FoxP3+ regulatory T cells in patients with hepatocellular carcinoma.
Feng X; Li B; Ye H; Long D
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):309-14. PubMed ID: 21633918
[TBL] [Abstract][Full Text] [Related]
7. Increased frequency and FOXP3 expression of human CD8
Zahran AM; Nafady-Hego H; Mansor SG; Abbas WA; Abdel-Malek MO; Mekky MA; Hetta HF
Hum Immunol; 2019 Jul; 80(7):510-516. PubMed ID: 30904437
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells, especially ICOS
Tu JF; Ding YH; Ying XH; Wu FZ; Zhou XM; Zhang DK; Zou H; Ji JS
Sci Rep; 2016 Oct; 6():35056. PubMed ID: 27725696
[TBL] [Abstract][Full Text] [Related]
9. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer.
Pedroza-Gonzalez A; Verhoef C; Ijzermans JN; Peppelenbosch MP; Kwekkeboom J; Verheij J; Janssen HL; Sprengers D
Hepatology; 2013 Jan; 57(1):183-94. PubMed ID: 22911397
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy.
Zhang CY; Liu S; Yang M
World J Gastroenterol; 2022 Jul; 28(27):3346-3358. PubMed ID: 36158267
[TBL] [Abstract][Full Text] [Related]
11. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis.
Chen KJ; Lin SZ; Zhou L; Xie HY; Zhou WH; Taki-Eldin A; Zheng SS
PLoS One; 2011; 6(9):e24671. PubMed ID: 21935436
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting effect of Astragalus polysaccharides on the functions of CD4+CD25 highTreg cells in the tumor microenvironment of human hepatocellular carcinoma.
Li Q; Bao JM; Li XL; Zhang T; Shen XH
Chin Med J (Engl); 2012 Mar; 125(5):786-93. PubMed ID: 22490576
[TBL] [Abstract][Full Text] [Related]
13. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.
Kobayashi N; Hiraoka N; Yamagami W; Ojima H; Kanai Y; Kosuge T; Nakajima A; Hirohashi S
Clin Cancer Res; 2007 Feb; 13(3):902-11. PubMed ID: 17289884
[TBL] [Abstract][Full Text] [Related]
14. Treg plasticity and human diseases.
Zhang Z; Guo J; Jia R
Inflamm Res; 2023 Dec; 72(12):2181-2197. PubMed ID: 37878023
[TBL] [Abstract][Full Text] [Related]
15. Human hepatocellular carcinoma-infiltrating CD4⁺CD69⁺Foxp3⁻ regulatory T cell suppresses T cell response via membrane-bound TGF-β1.
Han Y; Yang Y; Chen Z; Jiang Z; Gu Y; Liu Y; Xu S; Lin C; Pan Z; Zhou W; Cao X
J Mol Med (Berl); 2014 May; 92(5):539-50. PubMed ID: 24668348
[TBL] [Abstract][Full Text] [Related]
16. Th17, synchronically increased with T
Wang W; Wang Z; Qin Y; Tang G; Cai G; Liu Y; Zhang J; Zhang P; Shen Q; Shen L; Yu W
Clin Exp Immunol; 2018 May; 192(2):181-192. PubMed ID: 29271479
[TBL] [Abstract][Full Text] [Related]
17. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
18. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients.
Li F; Guo Z; Lizée G; Yu H; Wang H; Si T
Clin Chem Lab Med; 2014 Sep; 52(9):1357-65. PubMed ID: 24646790
[TBL] [Abstract][Full Text] [Related]
19. [Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients].
Zhang HH; Fei R; Xie XW; Wang L; Luo H; Wang XY; Wei L; Chen HS
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 41(3):313-8. PubMed ID: 19727215
[TBL] [Abstract][Full Text] [Related]
20. Expansion of peripheral and intratumoral regulatory T-cells in hepatocellular carcinoma: a case-control study.
Thakur S; Singla A; Chawla Y; Rajwanshi A; Kalra N; Arora SK
Indian J Pathol Microbiol; 2011; 54(3):448-53. PubMed ID: 21934201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
